Related references
Note: Only part of the references are listed.Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial
Byeong-Ho Park et al.
LANCET ONCOLOGY (2008)
The targeted oncolytic poxvirus JX-594 demonstrates antitumoral, antivascular, and anti-HBV activities in patients with hepatocellular carcinoma
Ta-Chiang Liu et al.
MOLECULAR THERAPY (2008)
Rational strain selection and engineering creates a broad-spectrum, systemically effective oncolytic poxvirus, JX-963
Steve H. Thorne et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
Oncolytic virotherapy with an HSV amplicon vector expressing granulocyte-macrophage colony-stimulating factor using the replication-competent HSV type 1 mutant HF10 as a helper virus
S-i Kohno et al.
CANCER GENE THERAPY (2007)
Use of an oncolytic virus secreting GM-CSF as combined oncolytic and immunotherapy for treatment of colorectal and hepatic adenocarcinomas
Sandeep Malhotra et al.
SURGERY (2007)
Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF
J. H. Kim et al.
MOLECULAR THERAPY (2006)
CG0070, a conditionally replicating granulocyte macrophage colony-stimulating factor-armed oncolytic adenovirus for the treatment of bladder cancer
N Ramesh et al.
CLINICAL CANCER RESEARCH (2006)
Generation of dendritic cells from rabbit bone marrow mononuclear cell cultures supplemented with hGM-CSF and hIL-4
V Cody et al.
VETERINARY IMMUNOLOGY AND IMMUNOPATHOLOGY (2005)
Share Paper
